One clinical implication of these findings is that molecular profiling of archival tumor samples collected from the primary disease site may not provide an accurate assessment of ERBB2 mutational and HER2 expression status in patients with urothelial cancer, in particular in patients with significant intervening therapy. Here, ERBB2 is linked to neoplasm.